Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate--the relationship between dose and clinical effect

P Seideman1

  • 1Department of Internal Medicine, Karolinska Institute, Danderyd Hospital, Sweden.

British Journal of Rheumatology
|August 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Controlled trial of methotrexate in patients with severe chronic asthma.

European journal of clinical pharmacology·1996
Same author

Simultaneous quantitation of methotrexate and its two main metabolites in biological fluids by a novel solid-phase extraction procedure using high-performance liquid chromatography.

Journal of chromatography. B, Biomedical applications·1995
Same author

Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics.

European journal of clinical pharmacology·1995
Same author

Methotrexate in rheumatoid arthritis--a limited sampling strategy for estimation of the area under the plasma concentration versus time curve.

Therapeutic drug monitoring·1994
Same author

The stereoselective disposition of the enantiomers of ibuprofen in blood, blister and synovial fluid.

British journal of clinical pharmacology·1994
Same author

Reduced sulphoxidation capacity in D-penicillamine induced myasthenia gravis.

Clinical rheumatology·1994
Same journal

Sensorineural hearing loss, iritis and ankylosing spondylitis.

British journal of rheumatology·1999
Same journal

Outcome in systemic vasculitis.

British journal of rheumatology·1999
Same journal

Infection with an unenveloped DNA virus (TTV) associated with non-A to G hepatitis in patients with rheumatoid arthritis.

British journal of rheumatology·1999
Same journal

Aortitis in relapsing polychondritis.

British journal of rheumatology·1999
Same journal

Successful treatment with antithymocyte globulin and cyclosporin A of a severe aplastic anaemia associated with an eosinophilic fasciitis.

British journal of rheumatology·1999
Same journal

Haemophagocytic syndrome in a patient with dermatomyositis.

British journal of rheumatology·1999
See all related articles

Methotrexate (MTX) effectively treats rheumatoid arthritis (RA). This study found MTX dose-response varied individually, suggesting personalized dosing for better outcomes and fewer side effects.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Clinical Medicine

Background:

  • Methotrexate (MTX) is a widely used anti-rheumatic medication.
  • The precise relationship between MTX dosage and clinical efficacy in rheumatoid arthritis (RA) requires further clarification.

Purpose of the Study:

  • To investigate the dose-response relationship of various Methotrexate (MTX) doses in patients with rheumatoid arthritis (RA).
  • To determine the impact of different MTX dosages on key clinical and inflammatory markers.

Main Methods:

  • A randomized, double-blind study was conducted.
  • Four different doses of MTX (5 mg to 20 mg weekly) were administered to RA patients.
  • Clinical outcomes including Ritchie joint index, morning stiffness, pain, ESR, and C-reactive protein were assessed.

Related Experiment Videos

Main Results:

  • A 5 mg dose of MTX demonstrated significant improvements in the Ritchie joint index, morning stiffness, pain, ESR, and C-reactive protein.
  • A clear dose-dependent relationship was observed for MTX effects within the 5 to 20 mg weekly dosage range.
  • Significant interindividual variability in MTX dose-response curves was identified.

Conclusions:

  • MTX dosage should be individualized for each RA patient to optimize treatment efficacy.
  • Personalized MTX dosing strategies can potentially minimize dose-dependent adverse effects.
  • Understanding individual responses is key to maximizing therapeutic benefits of MTX in RA management.